Shire has posted a not-unexpected decline in sales for the second quarter, battered by generic competition to the company’s big earner, the attention-deficit hyperactivity disorder drug Adderall XR.

Net income came in at $44 million compared to a loss of $79 million for the like, while product sales were down 21% to $558.4 million. The fall was due to the introduction of an authorised generic version of Adderall XR (mixed amphetamine salts) by Teva Pharmaceutical Industries in April.

This led to a 77% crash in Adderall XR sales to $67.4 million. However, turnover from Vyvanse (lisdexamfetamine dimesylate), the follow-up to the older ADHD drug, leapt 75% to $114.2 million. A deal was signed in March with GlaxoSmithKline to co-promote Vyvanse and Shire will be hoping it results in increased marketed share for the drug.

Some analysts have been disappointed by the take-up of Vyvanse but Shire chief executive Angus Russell noted that the drug retained market share “during the historically quieter summer vacation season in contrast to other branded ADHD treatments”. He added that the company is looking forward to “increased sales momentum” from the GSK link-up.

Back to the figures, and sales of Shire’s ADHD patch product Daytrana (methylphenidate), sales fell 34% to $14.9 million, while revenues from Elaprase (idursulfase) for Hunter syndrome reached $85.3 million, up 6%. Turnover from Fosrenol (lanthanum carbonate) for high blood phosphate levels was up 17% to $49.6 million.

Replagal (agalsidase alfa), for the treatment of Fabry disease, contributed $44.4 million to the coffers, down 1%, while the ulcerative colitis therapy Pentasa (mesalamine) climbed 21% to $54.0 million. The firm’s newer ulcerative colitis drug Lialda/Mezavant brought in $54.6 million, a leap of 71%, while Firazyr (icatibant), for acute attacks of hereditary angioedema, which Shire gained when it bought Germany’s Jerini, had revenues of $1.5 million.

Mr Russell noted that excluding Adderall XR, sales were up 20% compared to the same quarter last year. He added that “a new phase of Shire’s development” has begun as “we have diversified into a broader portfolio of young products with strong intellectual property and exciting growth prospects”. It also has a presence in 26 countries compared to nine four years ago.

He concluded by saying that “supported by pro-active cost management”, Shire’s full-year guidance is unchanged and “we reiterate our aspiration of growing sales in the mid-teens range on average between 2009 and 2015.”

Analysts at Collins Stewart liked the look of the figures, noting that the second half will be a good one, as GSK helps with the promotion of Vyvanse and Shire moves its Gaucher disease compound velaglucerase alfa towards US approval. The broker also noted that the company’s new ADHD drug Intuniv (guanfacine) is on track for approval in the fourth quarter.